Sarepta Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.72 | -100% | -17.87 | -100% |
| P/S |
|
7.03 | 33.75 | -79.18% |
|
|
| P/BV |
|
10.17 | 4.82 | 111% |
|
|
| P/FCF |
|
-17.74 | 61 | -129.09% |
|
|
| Ev/Ebitda |
|
-36.23 | -22.17 | 63.41% |
|
|
| Ev/S |
|
7.8 | 22.56 | -65.4% |
|
|
| Ev/FCF |
|
-16.49 | 68.75 | -123.99% |
|
|
| E/P |
|
-0.0513 | 0.0178 | -388.63% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-21.54 | 4.98 | -532.81% | -75.54 | -71.48% |
| ROE |
|
-62.37 | 9.61 | -748.91% |
|
|
| ROA |
|
-16.42 | 0.3443 | -4869.07% |
|
|
| ROIC |
|
-17.31 | 7.63 | -326.74% |
|
|
| ROS |
|
-43.11 | -25.17 | 71.27% |
|
|
| ROCE |
|
-38.02 | 15.35 | -347.68% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-4.69 | -3.68 | 27.57% | -3.78 | +23.9% |
| Nеt Debt/Ebitda |
|
-3.62 | -3.44 | 5.21% |
|
|
| Debt/Ratio |
|
0.3847 | 0.1985 | 93.81% |
|
|
| Debt/Equity |
|
0.4906 | 1.66 | -70.49% |
|
|
| Debt/Net Income |
|
-2.34 | 10.32 | -122.7% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5473 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 1.07 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.498 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5473 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
226.51 | -56.89 | -498.15% | ||
| Growth impulse Ebitda in 5 years |
|
-6.43 | -54.68 | -88.24% | ||
| Growth impulse Net Income in 5 years |
|
-25.05 | -58.33 | -57.05% | ||
| Growth impulse FCF in 5 years |
|
13.32 | -49.48 | -126.92% | ||
| Growth impulse EPS in 5 years |
|
-40.26 | -32.41 | 24.22% |
IP Score
3.11/10
